{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-056252","form_type":"8-K","ticker":"AURA","cik":"0001501796","company_name":"Aura Biosciences, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.703806+00:00","generated_at":"2026-06-02T05:35:48.758367+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Aura Biosciences Q1 2024 net loss $19.7M; cash $202.9M funds into H2 2026","bullets":["Net loss of $19.7M for Q1 2024 vs $17.5M in Q1 2023; R&D spend $17.1M (up from $14.4M).","Cash and marketable securities $202.9M as of March 31, 2024; expected to fund operations into H2 2026.","Phase 3 CoMpass trial for small choroidal melanoma enrolling globally; target ~100 patients.","Phase 1 bladder cancer trial enrolling; early data expected mid-2024; Fast Track designation from FDA.","Appointed Conor Kilroy as General Counsel and Secretary."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-056252","json":"https://secwatch.observer/filing/0000950170-24-056252.json","markdown":"https://secwatch.observer/filing/0000950170-24-056252.md","text":"https://secwatch.observer/filing/0000950170-24-056252.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501796/000095017024056252/0000950170-24-056252-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501796/000095017024056252/aura-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T05:35:48.758367+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"392773f899de08864939fec8f783cb89656e2a92","claim":"Aura Biosciences, Inc. reported financial results for first quarter ended March 31, 2024.","evidence_excerpt":"Aura Biosciences, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1501796/000095017024056252/0000950170-24-056252-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}